A US buyer may see a Swiss biotech acquisition as a familiar combination of antitrust clearance, intellectual-property diligence and negotiated risk allocation. A pending Swiss investment-screening statute adds another question. The question is not whether the buyer is American. It is whether the buyer qualifies as a foreign state investor under Art. 2(d) IPG, whether the Swiss target carries a specified activity at the statutory scale, and whether the transaction conveys control. Even where that screen does not apply, the price may still depend on rights and permissions that cannot be moved by a purchase agreement alone.
1. When Would Swiss Investment Screening Reach a US Buyer?
Parliament adopted the IPG, the Swiss Investment Screening Act, on 19 December 2025. It had not entered into force by October 2026; the SECO planned commencement in 2027 and was not accepting applications. Art. 1(2) IPG addresses takeovers of Swiss companies by foreign state investors. Art. 2(a) IPG defines a takeover through direct or indirect control, which can arise by merger, a share purchase or a contract. This is not a nationality test for every cross-border acquisition. A private US corporation that neither falls under foreign state control nor acts for a foreign state organ falls outside that investor definition, even if the target operates in a sensitive sector. Foreign state control or action on a state organ’s behalf can bring the buyer within Art. 2(d) IPG, depending on the statutory investor category; a sovereign co-investment or state-pension stake calls for analysis of the investor’s form, main administration and actual rights.1Bundesgesetz über die Prüfung ausländischer Investitionen (Investitionsprüfgesetz, IPG) vom 19. Dezember 2025, BBl 2026 31, Art. 1–3 and 25 IPG.
The sector test is also narrower than a general life-sciences designation. Art. 3(2)(b) IPG names Swiss companies engaged in research, development, production or distribution of medicines, medical devices, vaccines or personal medical protective equipment. For this category the target must have generated average worldwide annual turnover of at least CHF 100 million in the two financial years before an application. The separate threshold of 50 full-time positions or CHF 10 million turnover in Art. 3(1) IPG belongs to different categories of military, infrastructure and security activity. A target that meets the life-sciences description but falls below its turnover threshold is not drawn into Art. 3(2)(b) IPG merely because it employs 50 people. A target with several activities may, however, meet another listed category, and control may be obtained over part of a company.
Upon commencement, Art. 3(2)(b) IPG would require approval for non-exempt foreign state investors acquiring control of qualifying Swiss life-sciences targets averaging at least CHF 100 million worldwide annual turnover in the two financial years before application.
The Federal Council's June 2026 draft IPV, the Investment Screening Ordinance, is not law. Annex 3 IPV (consultation draft) proposes exemptions for listed European states, but does not list the United States. Art. 7–8 IPV (consultation draft) also qualify which state actors can use an exemption and deny it where an investor acts for a non-exempt state's organ. The absence of the US from that draft matters only if the buyer is a foreign state investor under the IPG at all. A private US buyer neither controlled by nor acting for a foreign state organ needs no draft country exemption to avoid a regime confined to state investors; a US state-controlled buyer cannot infer an exemption from US nationality.2Vorentwurf Verordnung über die Prüfung ausländischer Investitionen (Investitionsprüfverordnung, IPV), Konsultationsfassung vom 12. Juni 2026, Art. 7–8 and Annex 3 draft IPV.
If the Act commences in the form adopted, an in-scope state investor must apply before completion under Art. 6 IPG. Art. 7 IPG allows one month after a complete application for direct approval or the opening of a fuller review; Art. 8 IPG provides three months from opening that review. Silence within those statutory periods can count as approval under Art. 9(1) IPG, but Art. 9(2) IPG permits extensions on specified grounds. Art. 8(4) IPG suspends the civil effectiveness of a notifiable takeover until approval. The Federal Council may order divestment under Art. 19 IPG, and Art. 20 IPG permits a sanction of up to ten percent of the Swiss target's relevant average worldwide annual turnover for specified violations. Those consequences describe the adopted statute's future operation, not an October 2026 filing obligation. The public-order test in Art. 4 IPG permits conditions and does not equate notification with refusal.
2. Which Ownership and Employment Rights Support the Price?
The screening question may be short for a privately controlled US buyer; the title question rarely is. A patent schedule identifies registrations, but not necessarily the inventor's chain of entitlement. Art. 332(1) OR assigns to the employer inventions made by an employee in the course of service and in performance of contractual duties, regardless of protectability. Art. 332(2) OR permits the employer to reserve in writing acquisition of inventions made in the course of service but outside contractual duties. The employee then has a written notice duty, the employer a six-month written election, and an appropriate special remuneration duty if the invention is retained under Art. 332(3)–(4) OR. Those are distinct paths for a scientist's work, not a general rule that an employment contract's broad US-style assignment language proves title in every result.3Bundesgesetz betreffend die Ergänzung des Schweizerischen Zivilgesetzbuches (Obligationenrecht, OR) vom 30. März 1911 (SR 220), Art. 332–333a and 340–340c OR. The distinction matters when the seller's value rests on a platform invented across academic appointments, consulting work and target employment. A registered patent may be valid as a patent while its commercial benefit is still contested through contract or compensation rights.
A share purchase ordinarily leaves the target as the same employer and contracting party. An asset purchase may move a business or part of one, which engages Art. 333(1) OR: employment transfers with its rights and duties unless an employee rejects. Art. 333a OR adds information and, where workforce measures are planned, consultation duties. The rule depends on transfer of an undertaking or part, not on the purchase of any isolated asset. It also does not transfer a founder's scientific judgment or a departing team's tacit know-how. The price attributed to those people therefore has a different legal basis from the price attributed to a patent or a machine.
Retention clauses may look stronger in an acquisition model than Swiss employment law permits. Art. 340 OR requires a written post-employment noncompete and access to customers or trade or manufacturing secrets whose use could substantially harm the employer. Art. 340a OR limits its place, time and subject and allows judicial reduction; Art. 340c OR causes the restraint to lapse in specified circumstances, including certain employer-initiated terminations. These are not merely drafting formalities. If a deal assumes that an inventor can be kept away from a competing laboratory for a fixed period, the commercial assumption depends on facts about access, harm, scope and the way employment ends. An earnout tied to continued development may distribute price risk, yet it cannot establish the seller's initial title or make an invalid restraint enforceable. The separate analysis of biotech earnout disputes shows why milestones can produce their own disputes.
Licensing and development relationships add another title-like question. The target may own a patent while a university, platform licensor or collaborator holds consent rights over a change of control. A CDMO agreement may condition assignment or continuity of supply on the transaction form. Those consequences come from the actual private instruments; no general Swiss statutory rule makes every license terminate on acquisition. The difference between a share sale, an asset transfer and an upstream control change may be decisive under a particular clause. It can also determine whether the buyer acquires the right to receive data, use materials or call on a supplier after completion. The agreement schedule describes conditional commercial rights whose value depends on the agreement’s actual wording.
3. Does a Product Authorization Follow the Transaction?
A Swiss pharmaceutical marketing authorization and the permission to operate a manufacturing site answer different questions. Art. 9 HMG generally requires an authorization before a ready-to-use medicine is marketed. Art. 10(1)(b)–(c) HMG requires the applicant to hold the relevant manufacture, import or wholesale license and have domicile, a registered office or a branch in Switzerland. A US parent can buy the Swiss holder's shares without necessarily changing the named Swiss legal person. That does not make the target's underlying license, compliance history or arrangements with manufacturers immaterial. A purchase of a product dossier or business assets that moves holder status to another entity is different.4Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG) vom 15. Dezember 2000 (SR 812.21), Art. 5 and 9–10 HMG.
Art. 10 VAM expressly permits transfer of a marketing authorization. That one sentence does not effect a transfer by itself.5Verordnung über die Arzneimittel (Arzneimittelverordnung, VAM) vom 21. September 2018 (SR 812.212.21), Art. 10 and 21–24 VAM. Swissmedic's transfer guidance requires the future holder to meet Art. 10 HMG when it applies, describes an application by that holder with an assignment declaration from the existing one, and normally expects a three-month lead before the planned transfer date. The guidance says all marketing-authorization duties pass at transfer; the new holder alone may release new batches for the market. In a transaction with products already manufactured under the former holder, the commercial closing date, Swissmedic's transfer decision, package information and release responsibility may therefore not line up automatically.6Swissmedic, Wegleitung Übertragung der Zulassung (ZL404_00_001, version 2.1, 1 July 2025), §§ 5.1.1–5.1.3.
Art. 5 HMG separately licenses manufacture. The AMBV ties that license to the operation's quality system, facilities, responsible technical person and scope. Art. 3–7 AMBV distinguish the licensed manufacturer's process responsibility and technical batch release from market release by the authorization holder's responsible person under Art. 13 AMBV. A change of ownership of the shares in a licensed company is not the same legal event as substituting a new manufacturer or importing entity. An asset deal that moves a plant, contracts or staff has to be understood against the license actually held and the operations the buyer proposes to perform. Regulatory permission has a holder and a defined activity; the seller's warranty is a risk allocation, not an administrative grant.7Verordnung über die Bewilligungen im Arzneimittelbereich (Arzneimittel-Bewilligungsverordnung, AMBV) vom 14. November 2018 (SR 812.212.1), Art. 3–7 and 11–14 AMBV.
For devices the identity of the manufacturer matters in another way. The Swiss MepV requires a foreign manufacturer to appoint a Swiss authorized representative by written mandate under Art. 51 MepV; the mandate and importer's obligations under Art. 53 MepV remain separate from a corporate acquisition.8Medizinprodukteverordnung (MepV) vom 1. Juli 2020 (SR 812.213), Art. 51 and 53 MepV. Under the EU Medical Device Regulation, a notified-body certificate is issued to one named manufacturer, and planned substantial changes to the approved quality system or device range engage notified-body review.9Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices [2017] OJ L117/1 (MDR), Art. 56 and Annexes IX and XII MDR. The EU in vitro diagnostic regime likewise issues a certificate to one named manufacturer.10Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices [2017] OJ L117/176 (IVDR), Art. 51 and Annex XII IVDR. A share purchase that leaves that manufacturer in place and an asset transaction that substitutes another manufacturer therefore present different conformity questions. Neither the certificate nor the CH-REP mandate is a generic item that the buyer can simply list as transferred. The result turns on the named manufacturer, the assessed device and the relevant conformity route, with any representative or notified-body arrangements examined on their own terms.
4. Which Data and Clearance Questions Can Change Deal Value?
A life-sciences target may be valued partly for a patient-linked dataset or biological samples. Those assets do not behave like assignable inventory. Art. 5(c) DSG classifies health and genetic data as specially protected personal data. Art. 16–17 DSG govern disclosure abroad through adequacy, safeguards and specified exceptions; Art. 30–31 DSG address personality infringement and possible justification. Neither company ownership nor a purchase price supplies a universal permission for a new use, new recipient or foreign disclosure.11Bundesgesetz über den Datenschutz (Datenschutzgesetz, DSG) vom 25. September 2020 (SR 235.1), Art. 5, 16–17 and 30–31 DSG. A share acquisition may leave the data controller's corporate identity intact while changing the commercial purposes and access arrangements around it. An asset transfer may change the recipient itself. Those distinctions cannot be solved solely by an information-technology migration plan.
The HFG adds research-specific conditions. Art. 32 HFG distinguishes biological material and genetic data in uncoded and coded form and permits certain anonymization after information and absent objection. Art. 33 HFG draws a different line for non-genetic health-related personal data. Art. 34 HFG allows use without the usual consent or information only where its cumulative conditions are met; it is not a general biobank-transfer exception. Art. 41 HFG restricts disclosure for nonresearch purposes. For research export, Art. 42(1) HFG addresses material and genetic data through informed consent, while Art. 42(2) HFG refers non-genetic health data to Art. 16–17 DSG. A target's consent language, data coding, collection history and planned post-acquisition use may therefore support different portions of the buyer's valuation.12Bundesgesetz über die Forschung am Menschen (Humanforschungsgesetz, HFG) vom 30. September 2011 (SR 810.30), Art. 32–35 and 41–43 HFG.
Competition clearance follows another set of thresholds. Art. 9 KG requires notification where, in the last financial year before the concentration, the parties together generated at least CHF 2 billion worldwide turnover or CHF 500 million Swiss turnover, and at least two parties each generated at least CHF 100 million Swiss turnover, subject to the prior-dominance route in Art. 9(4) KG. The in-force Art. 10 KG retains a qualified-dominance test. The 19 December 2025 KG amendment adopted a significant-impediment-to-effective-competition test, but SECO expects the law and its revised ordinances to commence together in 2027. Art. 62 KG, as adopted in the 19 December 2025 amendment, directs that the law in force when a notification is filed governs that transaction. A deal's Swiss merger-control analysis thus depends on filing timing as well as market structure; the IPG's target-turnover threshold cannot substitute for the KG's distinct party-turnover test.13Bundesgesetz über Kartelle und andere Wettbewerbsbeschränkungen (Kartellgesetz, KG) vom 6. Oktober 1995 (SR 251), Art. 9–10 KG.14Änderung des Kartellgesetzes vom 19. Dezember 2025, BBl 2026 18, Art. 10 and 62 KG. The distinct standards are explored in the Swiss merger-control analysis.
An EU footprint can add the EU FSR. For mandatory notification under Art. 20(3) and 22(1) FSR, at least one merging undertaking, the acquired undertaking or the joint venture must be established in the EU and have generated at least EUR 500 million in aggregate EU turnover in the preceding financial year. The specified parties must also have been granted combined third-country financial contributions of more than EUR 50 million during the three years before conclusion of the agreement, the public-bid announcement or acquisition of a controlling interest. Art. 3 FSR defines financial contributions more broadly than subsidies and includes grants, tax benefits and some public purchases. Art. 21(5) FSR also allows the Commission to request notification before implementation where it suspects that foreign subsidies may have been granted to the undertakings concerned in the three years before the concentration. The purchase of a Swiss corporation with no qualifying EU-established business does not meet the mandatory turnover limb merely because the buyer is American or receives public funding. Conversely, a Swiss legal target with an EU-established acquired business may raise the question even though Swiss investment screening is confined to state investors. The foreign subsidies analysis for biotech acquisitions treats the contribution test in greater depth.15Regulation (EU) 2022/2560 of the European Parliament and of the Council of 14 December 2022 on foreign subsidies distorting the internal market [2022] OJ L330/1 (FSR), Art. 20(3), 21(5) and 22(1) FSR.
5. Strategic Considerations for US Life-Sciences Acquirers
US counsel accustomed to HSR antitrust notification and the CFIUS inbound-investment review may expect one clearance map to settle the Swiss deal. The IPG instead depends on foreign state investor status and a Swiss statutory target category, while Swiss merger control uses its own party-turnover measures and the FSR turns on an EU business and third-country contributions. These tests can coexist without having the same filing party, evidence or commencement date. A contractual closing condition has to reflect the approval actually required, not the closest familiar US acronym.
Price protection is equally sensitive to legal form. If a Swiss company holds the drug authorization, device certificate, research consents and key contracts, how many of those positions remain with the same legal person after a share purchase? Which require a separate transfer or reassessment if the buyer instead acquires the assets? Does the inventor's work fall within Art. 332(1) OR or an Art. 332(2) OR reservation with a compensation consequence? What part of an earnout measures science and market performance, and what part silently depends on regulatory status or consent the buyer has not acquired? Those questions cannot be answered by treating a data room's asset list as a list of transferable rights.
The pending IPG adds a further timing question for a deal that may sign before commencement and close afterward. Art. 25 IPG gives the Federal Council the commencement decision; the draft IPV can still change. Whether a particular transaction will fall within the final rule depends on its eventual effective date, the final exemption text and the investor’s status and control arrangement at completion. A US buyer's tax counsel may separately examine structure, transfer taxes and allocation, but no tax result follows from the screening analysis. The decisive commercial issue is which part of the proposed price depends on a legally secure right and which part depends on a permission, counterparty or future event that the deal documents cannot themselves create.